Alexander Sapir
Net worth: 735 364 $ as of 29/06/2026
Net worth: 735 364 $ as of 29/06/2026
Mr. Alexander C.
Sapir is a President, Chief Executive Officer & Director at Fulcrum Therapeutics, Inc., an Independent Director at PhaseBio Pharmaceuticals, Inc. and a Chief Executive Officer & Director at ReViral Ltd. He is on the Board of Directors at Fulcrum Therapeutics, Inc., PhaseBio Pharmaceuticals, Inc. and ReViral Ltd. Mr. Sapir was previously employed as a President, Chief Executive Officer & Director by Dova Pharmaceuticals, Inc., an Executive Vice President-Marketing & Sales by United Therapeutics Corp., and a Senior Director-Marketing by Guilford Pharmaceuticals, Inc. He received his undergraduate degree from Franklin & Marshall College and an MBA from Harvard Business School.
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
| 30/03/2026 | 200,919 ( 0.3% ) | 735 364 $ | 29/06/2026 |
| Companies | Position | Start |
|---|---|---|
| PHASEBIO PHARMACEUTICALS, INC. | Director/Board Member | 11/02/2020 |
| FULCRUM THERAPEUTICS, INC. | Chief Executive Officer | 30/06/2023 |
ReViral Ltd.
ReViral Ltd. BiotechnologyHealth Technology Develops novel antiviral therapeutics | Chief Executive Officer | 09/06/2019 |
| Companies | Position | End |
|---|---|---|
| DOVA PHARMACEUTICALS, INC. | Chief Executive Officer | 30/11/2018 |
| UNITED THERAPEUTICS CORPORATION | Sales & Marketing | 30/04/2016 |
Guilford Pharmaceuticals, Inc.
Guilford Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops drugs used to treat neurological diseases | Sales & Marketing | 31/12/2004 |
Active
Inactive
Listed companies
Private companies
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
| Private companies | 8 |
|---|---|
Guilford Pharmaceuticals, Inc.
Guilford Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops drugs used to treat neurological diseases | Health Technology |
United Therapeutics Corp.
United Therapeutics Corp. BiotechnologyHealth Technology Operates as a biotechnology company that develops and commercializes products to address the unmet medical needs of patients with chronic & life-threatening conditions | Health Technology |
PhaseBio Pharmaceuticals, Inc.
PhaseBio Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Engages in development and commercialization of novel therapies for cardiovascular diseases | Health Technology |
Franklin & Marshall College
Franklin & Marshall College Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Harvard Business School
Harvard Business School Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
ReViral Ltd.
ReViral Ltd. BiotechnologyHealth Technology Develops novel antiviral therapeutics | Health Technology |
Fulcrum Therapeutics, Inc.
Fulcrum Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops medicines for patients by transforming gene regulation in disease | Health Technology |
Dova Pharmaceuticals, Inc.
Dova Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops and commercializes drugs with disorder of low blood platelet count | Health Technology |
Select your edition
All financial news and data tailored to specific country editions